ImmunityBio Inc. Stock
Price
Target price
€2.10
€2.10
3.090%
0.063
3.090%
-
11:17 / Tradegate
WKN: A2QQ2E / Name: ImmunityBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
ImmunityBio Inc. Stock
A very strong showing by ImmunityBio Inc. today, with an increase of €0.063 (3.090%) compared to yesterday's price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for ImmunityBio Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | 3.090% | -16.557% | -11.247% | -52.474% | -26.472% | -50.098% | -80.098% |
| Krystal Biotech | 1.150% | 7.992% | 13.308% | -22.753% | -10.775% | 89.930% | - |
| Ardelyx Inc. | 1.340% | 2.439% | 2.243% | -32.649% | -24.713% | 394.575% | -25.804% |
| Evolus Inc | -0.650% | -3.750% | 1.316% | -38.400% | -26.667% | -23.000% | 183.610% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
